Skip to content

Edo van Houten joins Gilbert as Chief Financial Officer

We are delighted to welcome Edo van Houten to Gilbert as our new Chief Financial Officer.

As Gilbert continues to grow, expand its international partnerships and prepare for its next stage of financing and commercialization, strengthening our leadership team is an important milestone. Edo’s appointment marks another significant step in building the company for long-term success.

Edo brings more than 20 years of executive financial leadership within the life sciences, MedTech and pharmaceutical industries. Throughout his career, he has helped innovative healthcare companies scale internationally, professionalize their organizations, execute strategic growth initiatives and successfully navigate financing and M&A transactions.

As CFO, Edo will lead Gilbert’s financial strategy, investor relations, governance and organizational development while supporting the continued growth of our Smart Precision Inhaler platform.

Maurits Huigen, CEO of Gilbert:

“I am pleased to welcome Edo to Gilbert. His experience in scaling innovative healthcare companies, combined with his strategic mindset and collaborative leadership style, makes him an outstanding addition to our executive team. As we prepare for our Series A financing and the next phase of our company’s growth, Edo’s expertise will be invaluable in helping us realize our ambition of bringing next-generation inhalation therapies to patients around the world.”

Edo van Houten, CFO of Gilbert:

“I am excited to join Gilbert at such an important stage in its development. The company has developed an impressive technology platform with the potential to make a meaningful difference for patients and pharmaceutical partners alike. I look forward to working with the talented Gilbert team to help build a strong, scalable organization and support the company’s continued growth and international ambitions.”

Welcome aboard, Edo!

 

Gilbert is developing the next generation of soft mist inhalers based on a proprietary electrospray (Electro Hydrodynamic Atomization or EHDA) technology to redefine treatment for patients with the next generation of inhaled therapies. Gilbert’s breath actuated smart precision inhaler creates a monodispersed soft mist aerosol, with a customizable droplet size enabling more precise targeting of drugs to desired regions of the lungs, which has the potential to improve the efficacy and safety of treatments. Electrospray enables gentle, efficient delivery of both small and large molecule therapies in both solution and suspension formulations.

Visit us at Gilbert | Redefining treatment for lung patients, follow us on Linkedin or contact us at info@gilbert.eu to learn if electrospray is suitable for your application.

Other posts

Let’s stay in touch!

Stay up-to-date with Gilbert’s latest news, vacancies and achievements by following us on social media.